Alpha Teknova (TKNO) to Release Earnings on Wednesday

Alpha Teknova (NASDAQ:TKNO) is anticipated to release its Q1 2026 results after the market closes on Wednesday, May 6th. Analysts expect Alpha Teknova to post earnings of ($0.0926) per share and revenue of $10.2260 million for the quarter. Interested persons can find conference call details on the company’s upcoming Q1 2026 earning report page for the latest details on the call scheduled for Wednesday, May 6, 2026 at 6:00 PM ET.

Alpha Teknova (NASDAQ:TKNO) last announced its earnings results on Thursday, February 26th. The company reported ($0.09) earnings per share for the quarter, meeting the consensus estimate of ($0.09). Alpha Teknova had a negative return on equity of 23.32% and a negative net margin of 42.59%.The firm had revenue of $9.98 million during the quarter, compared to the consensus estimate of $9.62 million.

Alpha Teknova Stock Performance

NASDAQ:TKNO traded up $0.16 during mid-day trading on Monday, hitting $3.56. 23,968 shares of the company’s stock traded hands, compared to its average volume of 197,389. The firm has a 50 day moving average of $2.78 and a two-hundred day moving average of $3.62. Alpha Teknova has a 12 month low of $1.91 and a 12 month high of $7.48. The firm has a market capitalization of $190.58 million, a price-to-earnings ratio of -10.77 and a beta of 0.47. The company has a current ratio of 4.58, a quick ratio of 3.64 and a debt-to-equity ratio of 0.19.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings restated a “sell (d-)” rating on shares of Alpha Teknova in a research note on Monday, April 20th. One research analyst has rated the stock with a Strong Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company has a consensus rating of “Hold” and an average price target of $8.00.

Insider Activity at Alpha Teknova

In other news, CEO Stephen Gunstream acquired 26,000 shares of Alpha Teknova stock in a transaction on Friday, March 6th. The stock was bought at an average price of $2.15 per share, for a total transaction of $55,900.00. Following the transaction, the chief executive officer owned 269,497 shares of the company’s stock, valued at $579,418.55. The trade was a 10.68% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is accessible through this link. Corporate insiders own 12.50% of the company’s stock.

Institutional Trading of Alpha Teknova

A number of institutional investors and hedge funds have recently modified their holdings of TKNO. Balyasny Asset Management L.P. increased its position in shares of Alpha Teknova by 19.5% during the second quarter. Balyasny Asset Management L.P. now owns 1,000,484 shares of the company’s stock valued at $4,912,000 after purchasing an additional 163,526 shares during the period. Massar Capital Management LP increased its position in shares of Alpha Teknova by 185.7% during the second quarter. Massar Capital Management LP now owns 200,000 shares of the company’s stock valued at $982,000 after purchasing an additional 130,000 shares during the period. Geode Capital Management LLC increased its position in shares of Alpha Teknova by 64.4% during the second quarter. Geode Capital Management LLC now owns 298,850 shares of the company’s stock valued at $1,468,000 after purchasing an additional 117,016 shares during the period. Squarepoint Ops LLC bought a new stake in shares of Alpha Teknova during the third quarter valued at approximately $518,000. Finally, Jane Street Group LLC bought a new stake in shares of Alpha Teknova during the fourth quarter valued at approximately $239,000. 13.81% of the stock is currently owned by institutional investors.

Alpha Teknova Company Profile

Alpha Teknova, Inc (NASDAQ: TKNO) is a life science tools and reagents company that develops, manufactures and distributes proprietary products to support research, drug discovery and biomanufacturing. Its offerings target academic institutions, pharmaceutical and biotechnology firms, and diagnostic developers, with a focus on high-purity reagents and optimized workflows designed to accelerate molecular biology and protein science applications.

The company’s portfolio includes molecular biology reagents, cell culture buffers, in vitro translation kits, custom recombinant proteins, high-throughput screening buffers and other specialized formulations.